Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
Wendy L. Schoppert, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the transaction she directly owns 369 shares and indirectly owns 2,525 shares through the Wendy L. Schoppert Revocable Trust. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing shows a routine insider acquisition by a director and discloses the split between direct and indirect beneficial ownership.
Dennis W. Pullin, a director of DaVita Inc. (DVA), reported an acquisition of 369 shares of DaVita common stock on 08/15/2025 under a non-derivative transaction coded as an acquisition. The filing shows the price per share as $0 and states he beneficially owns 1,678 shares following the transaction, held in a direct capacity.
Form 4 summary: Berkshire Hathaway Inc. and Warren E. Buffett reported an insider sale of DaVita Inc. (DVA) common stock.
Key facts:
- Transaction date: 07/31/2025.
- Sold 1,635,962 shares of Common Stock at $140.6052 per share.
- Amount of securities beneficially owned following the transaction: 32,160,579 (indirect).
- Footnote ownership: 15,528,491 shares held by Government Employees Insurance Company (GEICO), and 16,632,088 shares held by two pension plans (BNSF Master Retirement Trust: 6,100,000; Berkshire Hathaway Inc. Consolidated Pension Plan: 10,532,088).
- Form signed by Warren E. Buffett on 08/04/2025.
DaVita Inc. (DVA) Form 4: Chief Compliance Officer James O. Hearty sold 2,351 common shares on 07/23/2025 at $150.00 each under a pre-arranged Rule 10b5-1 trading plan adopted 03/17/2025. The transaction reduced his direct holdings from an estimated 28,389 to 26,038 shares, a decline of roughly 8.3%. No derivative securities were involved. The filing was signed by an attorney-in-fact on 07/24/2025.
The sale represents a modest portion of the insider’s stake and was executed via an automated plan, which may limit informational value regarding management’s outlook. Investors typically monitor insider activity for sentiment signals, trading-plan usage, and potential supply impacts on the stock’s float.